Genmab AS's Total Assets for the quarter that ended in Dec. 2024 was $6,432 Mil.
Warning Sign:
If a company builds assets at 34.3% a year, faster than its revenue growth rate of 28.9% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Genmab AS's average Total Assets Growth Rate was 245.40% per year.
During the past 3 years, the average Total Assets Growth Rate was 67.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 34.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 49.80% per year.
During the past 13 years, Genmab AS's highest 3-Year average Total Assets Growth Rate was 133.50%. The lowest was -55.50%. And the median was 30.15%.
Total Assets is connected with ROA %. Genmab AS's annualizedROA % for the quarter that ended in Dec. 2024 was 35.01%. Total Assets is also linked to Revenue through Asset Turnover. Genmab AS's Asset Turnover for the quarter that ended in Dec. 2024 was 0.15.
Genmab AS Total Assets Historical Data
The historical data trend for Genmab AS's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Genmab AS's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Genmab AS's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Genmab AS Total Assets Related Terms
Thank you for viewing the detailed overview of Genmab AS's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GNMSF has been successfully added to your 